Clinical trial results for Tepezza, the only thyroid eye disease (TED) treatment approved by the US Food and Drug Administration (FDA), have associated the drug with hyperglycaemia in 10% of patients.
Presenting the results at June 2022’s Endocrine Society conference in Atlanta, US, authors noted that 63% of affected patients had pre-existing diabetes and their symptoms were controlled with medication. Results of the phase 2 and 3 trials also demonstrated Tepezza markedly improves TED symptoms including proptosis and diplopia.
“It is strongly recommended and emphasised that blood sugar levels be evaluated and monitored in all individuals treated with Tepezza, and not just those with diabetes,” said Dr Terry Smith, study author and endocrinologist at the Kellogg Eye Center-Michigan Medicine and University of Michigan.
